Pembrolizumab 100mg 4mL Gastrointestinal Cancer Treatment PD-1 Target

 inherit;">Generic Name:Pabolizumab Injection

Trade Name:Keytruda

English name: Pembrolizumab Injection

Hanyu Pinyin. Pabolizhu Dankang Zhusheye

Indications melanomaPapolizumab is indicated for the treatment of unresectable or metastatic melanoma that has failed first-line therapy


. Non-Small Cell Lung CancerPembrolizumab is indicated for the treatment of non-small-cell lung cancer patients with mutation-negative epidermal growth factor receptor (EGFR) gene. EGFR) gene in non-small cell lung cancer (NSCLC) and mesenchymal lymphoma proportional score (TPS) ≥1% as assessed by an NDA-approved PD-L1 tumor assay. Barr tumor kinase (ALK)-negative locally advanced or metastatic NSCLC as first-line monotherapy. Pembrolizumab in combination with pemetrexed and platinum-based chemotherapy is indicated as first-line treatment for the kinase (ALK) in metastatic non-squamous non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-negative and negative for mesenchymal lymphoma. Pembrolizumab, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Esophageal CancerPembrolizumab monotherapy is indicated for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). These patients have failed prior first-line systemic therapy and have tumors evaluated by well-validated assays that express a PD-L1 composite positivity score (CPS) ≥10.Head and Neck Squamous Cell CarcinomaPapolizumab monotherapy is indicated as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors were assessed to express PD-L1 (Composite Positive Score (CPS)) ≥20) as determined by a well-validated assay. Colorectal CancerPapolizumab monotherapy for the first-line treatment of unresectable or metastatic recurrent head and neck squamous cell carcinoma (HNSCC) with high microsatellite instability (MSI- H) or mismatch repair gene. H) or defective mismatch repair (dMMR) colorectal cancer (CRC) patients with unresectable or metastatic high microsatellite instability (MSI- H) or defective mismatch repair (dMMR), in which the KRAS, NRAS, and BRAF genes are present in the wild-type. [storage]. Store the vials in their original packaging, refrigerated at 2°C to 8°C, protected from light, frozen and shaken.